Skip Navigation LinksHome > February 2014 - Volume 34 - Issue 2 > INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR RET...
Retina:
doi: 10.1097/IAE.0b013e3182979e62
Original Study

INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR RETINAL ANGIOMATOUS PROLIFERATION IN TREATMENT-NAIVE EYES: Long-term Functional and Anatomical Results Using A Modified PrONTO-Style Regimen

Gharbiya, Magda MD, FEBO*; Parisi, Francesco MD*; Cruciani, Filippo MD*; Bozzoni-Pantaleoni, Francesco MD; Pranno, Federica MD*; Abdolrahimzadeh, Solmaz MD*

Collapse Box

Abstract

Purpose:

To evaluate long-term outcome of intravitreal anti–vascular endothelial growth factor monotherapy in retinal angiomatous proliferation.

Methods:

Twenty-one treatment-naive eyes were included in this prospective, interventional case series. Treatment was three monthly injections of bevacizumab and/or ranibizumab with a modified PrONTO-style regimen. Best-corrected visual acuity (BCVA) was evaluated. The influence of baseline BCVA and pretreatment pigment epithelial detachment on BCVA outcome or retreatment were assessed by Pearson correlation analysis.

Results:

Results were evaluated at 2 years and 3 years for 21 and 13 eyes, respectively. Mean baseline BCVA improved significantly from 44.5 (±11.0) (20/32) to 51.1 (±9.7) (20/24) and 50.8 (±10.4) letters (20/24) at 2 and 3 years, respectively (P = 0.02 and P = 0.049). Pigment epithelial detachment correlated negatively with BCVA outcome (r = −0.65, P = 0.002 and r = −0.67, P = 0.01 at 2 years and 3 years, respectively) and was significantly associated with retreatment (r = 0.62, P = 0.003 and r = 0.87, P < 0.0001 at 2 years and 3 years, respectively). Complete occlusion of the lesion was obtained in 71% and 69% of eyes at 2 years and 3 years, respectively, with a mean of 9.4 injections at 3 years.

Conclusion:

Intravitreal anti–vascular endothelial growth factor monotherapy was a valid option for retinal angiomatous proliferation. Stable or improved visual acuity was obtained in 95% and 100% of eyes at 2 years and 3 years, respectively.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.